logo
Share SHARE
FONT-SIZE Plus   Neg

ZIOPHARM Oncology COO Richard Bagley Steps Down

Biopharmaceutical company ZIOPHARM Oncology, Inc. (ZIOP) said Monday that the company's President, Chief Operating Officer and Director Richard Bagley is leaving the company and stepping down from the company's board of Directors.

The company also noted that Mark Thornton, Executive Vice President, Government Affairs, Health Policy and Advocacy and Chief Quality Compliance Officer, is also leaving ZIOPHARM to pursue other opportunities.

The company said that the President of Research and Development and Chief Medical Officer, Hagop Youssoufian, will assume the additional responsibility of oversight of all regulatory affairs and clinical operations. Also Caesar Belbel, Executive Vice President, Chief Legal Officer and Secretary, will shoulder the additional responsibility for corporate and business development.

The company also noted that Jason Amello, Executive Vice President and Chief Financial Officer, will continue to be responsible for finance and information technology, and Lynn Ferrucci, Senior Vice President, Human Resources, will continue to oversee human resources.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
HSBC is reportedly laying off about 100 of its senior investment bankers worldwide, as the banking giant strives to curb operating costs. According to reports, the London-headquartered bank will eliminate managing director and director level employees at the Global Banking and Markets division, as... Samsung Electronics Co., Ltd. (SMSN.L, SSNNF.OB, SSNLF.OB) will reportedly blame faulty batteries for last year's Galaxy Note 7 fiasco. According to a Wall Street Journal report, Samsung's investigation of Galaxy Note 7 smartphones found that some batteries were irregularly sized while others had... Federal investigators have closed their probe of a fatal crash that involved a Tesla Motors Inc. car eight months ago. The regulators said they have found no safety defects in the vehicle's automated driving system and that Tesla's Autopilot-enabled vehicles did not need to be recalled.
comments powered by Disqus
Follow RTT